CD44+CD24− cell populations have been found to have the greatest tumor-initiating potential in breast cancer [1,11] and have been used, either alone or in combination with other markers (CD133, EpCAM, CD49f, CD90, and CD61) [1,3], to identify and isolate breast cancer stem cells (BCSCs). This evidence concerns the gene EPCAM and breast carcinoma.